Sign in or create an account to add this stock to your watchlist.
About ConforMIS (NASDAQ:CFMS)
ConforMIS, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides ConforMIS Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, and Monaco. ConforMIS, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CFMS
CUSIPN/A
Phone781-345-9001
Debt
Debt-to-Equity Ratio0.49
Current Ratio5.95
Quick Ratio5.34
Price-To-Earnings
Trailing P/E Ratio-1.07
Forward P/E Ratio-1.60
P/E GrowthN/A
Sales & Book Value
Annual Sales$78.11 million
Price / Sales1.04
Cash FlowN/A
Price / CashN/A
Book Value$1.02 per share
Price / Book1.30
Profitability
EPS (Most Recent Fiscal Year)($1.24)
Net Income$-53,580,000.00
Net Margins-62.63%
Return on Equity-83.49%
Return on Assets-46.31%
Miscellaneous
Employees350
Outstanding Shares60,910,000
ConforMIS (NASDAQ:CFMS) Frequently Asked Questions
What is ConforMIS's stock symbol?
ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."
How were ConforMIS's earnings last quarter?
ConforMIS (NASDAQ:CFMS) posted its earnings results on Wednesday, May, 2nd. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.25) by $0.03. The medical instruments supplier earned $19.66 million during the quarter, compared to the consensus estimate of $19.51 million. ConforMIS had a negative net margin of 62.63% and a negative return on equity of 83.49%. View ConforMIS's Earnings History.
When is ConforMIS's next earnings date?
What price target have analysts set for CFMS?
6 equities research analysts have issued twelve-month price objectives for ConforMIS's stock. Their predictions range from $3.00 to $5.00. On average, they anticipate ConforMIS's stock price to reach $4.00 in the next year. View Analyst Ratings for ConforMIS.
What are Wall Street analysts saying about ConforMIS stock?
Here are some recent quotes from research analysts about ConforMIS stock:
- 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (4/18/2018)
- 2. Canaccord Genuity analysts commented, "We recently had the opportunity to host a fireside chat with ConforMIS management as well as visit the company’s booth at AAOS. Overall, we came away incrementally positive on the opportunities ahead of ConforMIS and continue to think commercial momentum through the H1/18 could represent an inflection point in the business. Specifically, we think the commercial changes implemented mid-2017, including new leadership, sales rep hiring, and the build-out of a corporate accounts team position the company with the opportunity for increased productivity into the H2/18. From our recent meetings with management, we highlight additional clinical data that bolsters the company’s implant technology and a strong product pipeline that should support market momentum over the next several years." (3/12/2018)
Who are some of ConforMIS's key competitors?
Who are ConforMIS's key executives?
ConforMIS's management team includes the folowing people:
- Mr. Mark A. Augusti, CEO, Pres & Director (Age 52)
- Dr. Philipp Lang M.D., MBA, Founder & Director (Age 55)
- Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 54)
- Dr. Daniel Steines M.D., MS, Chief Technology Officer (Age 49)
- Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 52)
When did ConforMIS IPO?
(CFMS) raised $135 million in an IPO on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.
Has ConforMIS been receiving favorable news coverage?
News headlines about CFMS stock have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ConforMIS earned a daily sentiment score of 0.12 on Accern's scale. They also assigned headlines about the medical instruments supplier an impact score of 48.25 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are ConforMIS's major shareholders?
ConforMIS's stock is owned by a number of of retail and institutional investors. Top institutional investors include Archon Capital Management LLC (4.99%), BlackRock Inc. (3.94%), Sio Capital Management LLC (3.61%), Platinum Investment Management Ltd. (0.98%), Northern Trust Corp (0.88%) and Millennium Management LLC (0.68%). Company insiders that own ConforMIS stock include Bradley Langdale, Daniel Steines, David Cerveny, Kenneth P Fallon III, Mark A Augusti, Paul S Weiner and Philipp Lang. View Institutional Ownership Trends for ConforMIS.
Which institutional investors are selling ConforMIS stock?
CFMS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have sold ConforMIS company stock in the last year include Bradley Langdale, Daniel Steines, David Cerveny, Mark A Augusti, Paul S Weiner and Philipp Lang. View Insider Buying and Selling for ConforMIS.
Which institutional investors are buying ConforMIS stock?
CFMS stock was acquired by a variety of institutional investors in the last quarter, including Archon Capital Management LLC, Sio Capital Management LLC, Platinum Investment Management Ltd., Allianz Asset Management GmbH, Northern Trust Corp, Schwab Charles Investment Management Inc., BlackRock Inc. and Altrinsic Global Advisors LLC. View Insider Buying and Selling for ConforMIS.
How do I buy shares of ConforMIS?
Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ConforMIS's stock price today?
One share of CFMS stock can currently be purchased for approximately $1.33.
How big of a company is ConforMIS?
ConforMIS has a market capitalization of $81.01 million and generates $78.11 million in revenue each year. The medical instruments supplier earns $-53,580,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. ConforMIS employs 350 workers across the globe.
How can I contact ConforMIS?
ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]
MarketBeat Community Rating for ConforMIS (CFMS)
MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
ConforMIS (NASDAQ:CFMS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for ConforMIS in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 200.75%. The high price target for CFMS is $5.00 and the low price target for CFMS is $3.00. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Hold |
| Consensus Rating Score: | 2.50 | 2.57 | 2.33 | 2.40 |
| Ratings Breakdown: | 1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.00 | $4.75 | $4.90 | $6.1250 |
| Price Target Upside: | 200.75% upside | 249.26% upside | 308.33% upside | 73.02% upside |
ConforMIS (NASDAQ:CFMS) Consensus Price Target History
ConforMIS (NASDAQ:CFMS) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
ConforMIS (NASDAQ:CFMS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ConforMIS (NASDAQ CFMS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.59%
Institutional Ownership Percentage: 44.04%
ConforMIS (NASDAQ CFMS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/16/2018 | Daniel Steines | Insider | Sell | 3,480 | $1.30 | $4,524.00 | 241,281 |  |
| 5/16/2018 | Mark A Augusti | CEO | Sell | 7,638 | $1.30 | $9,929.40 | 592,805 | |
| 5/16/2018 | Paul S Weiner | CFO | Sell | 3,711 | $1.30 | $4,824.30 | 319,290 | |
| 5/2/2018 | Bradley Langdale | Director | Sell | 9,465 | $1.35 | $12,777.75 | 21,304 | |
| 4/30/2018 | Daniel Steines | Insider | Sell | 277,064 | $1.41 | $390,660.24 | 232,307 | |
| 4/30/2018 | Philipp Lang | Director | Sell | 651,212 | $1.38 | $898,672.56 | 95,055 | |
| 4/26/2018 | Bradley Langdale | Director | Sell | 75,764 | $1.52 | $115,161.28 | 95,055 | |
| 4/26/2018 | Daniel Steines | CTO | Sell | 13,900 | $1.51 | $20,989.00 | 232,307 | |
| 2/6/2018 | Daniel Steines | Insider | Sell | 3,632 | $1.30 | $4,721.60 | 142,963 | |
| 2/6/2018 | Paul S Weiner | CFO | Sell | 2,674 | $1.30 | $3,476.20 | 157,009 | |
| 2/6/2018 | Philipp Lang | Director | Sell | 3,737 | $1.30 | $4,858.10 | 590,375 | |
| 12/19/2017 | David Cerveny | Insider | Sell | 5,478 | $2.27 | $12,435.06 | 152,073 | |
| 12/19/2017 | Mark A Augusti | CEO | Sell | 16,548 | $2.27 | $37,563.96 | 285,007 | |
| 12/19/2017 | Paul S Weiner | CFO | Sell | 7,433 | $2.27 | $16,872.91 | 167,116 | |
| 12/5/2017 | Mark A Augusti | CEO | Sell | 4,189 | $2.68 | $11,226.52 | 236,163 | |
| 11/15/2017 | Daniel Steines | CTO | Sell | 15,485 | $3.15 | $48,777.75 | 254,652 | |
| 11/15/2017 | David Cerveny | Insider | Sell | 16,392 | $3.17 | $51,962.64 | 151,408 | |
| 11/15/2017 | Paul S Weiner | CFO | Sell | 17,723 | $3.17 | $56,181.91 | 162,009 | |
| 10/18/2017 | Daniel Steines | CTO | Sell | 907 | $3.51 | $3,183.57 | 254,652 | |
| 10/18/2017 | Philipp Lang | Director | Sell | 1,839 | $3.53 | $6,491.67 | 594,112 | |
| 6/20/2017 | Bradley Langdale | Director | Sell | 6,722 | $4.30 | $28,904.60 | 26,533 | |
| 4/26/2017 | Daniel Steines | Insider | Sell | 5,000 | $5.54 | $27,700.00 | 190,745 | |
| 4/5/2017 | Daniel Steines | Insider | Sell | 5,000 | $5.00 | $25,000.00 | 195,745 | |
| 2/15/2017 | Philipp Lang | Director | Sell | 137,968 | $8.60 | $1,186,524.80 | 558,759 | |
| 2/3/2017 | David Cerveny | Insider | Sell | 3,569 | $8.59 | $30,657.71 | 87,501 | |
| 2/3/2017 | Paul S Weiner | CFO | Sell | 2,676 | $8.42 | $22,531.92 | 82,115 | |
| 2/3/2017 | Philipp Lang | Director | Sell | 108,705 | $8.60 | $934,863.00 | 519,411 | |
| 1/25/2017 | Philipp Lang | Director | Sell | 108,985 | $8.60 | $937,271.00 | 558,153 | |
| 1/23/2017 | Philipp Lang | Director | Sell | 9,681 | $8.60 | $83,256.60 | 519,784 | |
| 1/13/2017 | Philipp Lang | Director | Sell | 37,275 | $8.60 | $320,565.00 | 514,769 | |
| 1/11/2017 | Philipp Lang | Director | Sell | 2,800 | $8.62 | $24,136.00 | 516,019 | |
| 1/10/2017 | Philipp Lang | Director | Sell | 83,909 | $8.64 | $724,973.76 | 516,119 | |
| 1/9/2017 | Philipp Lang | Director | Sell | 6,200 | $8.65 | $53,630.00 | 516,119 | |
| 1/5/2017 | Philipp Lang | Director | Sell | 400 | $8.60 | $3,440.00 | 514,719 | |
| 1/3/2017 | Philipp Lang | Director | Sell | 74,876 | $8.00 | $599,008.00 | 589,495 | |
| 12/30/2016 | Philipp Lang | Director | Sell | 168,734 | $8.25 | $1,392,055.50 | 547,639 | |
| 12/28/2016 | Philipp Lang | Director | Sell | 58,547 | $8.26 | $483,598.22 | 532,981 | |
| 12/27/2016 | Philipp Lang | Director | Sell | 42,086 | $8.57 | $360,677.02 | 520,939 | |
| 12/23/2016 | Philipp Lang | Director | Sell | 30,647 | $8.62 | $264,177.14 | 520,939 | |
| 10/17/2016 | Daniel Steines | Insider | Sell | 889 | $8.64 | $7,680.96 | 214,324 | |
| 10/17/2016 | Paul S Weiner | CFO | Sell | 884 | $8.60 | $7,602.40 | 84,791 | |
| 10/12/2016 | Daniel Steines | Insider | Sell | 10,000 | $9.66 | $96,600.00 | 215,213 | |
| 10/5/2016 | Philipp Lang | CEO | Sell | 53,860 | $10.19 | $548,833.40 | 483,378 | |
| 10/4/2016 | Philipp Lang | CEO | Sell | 400 | $10.00 | $4,000.00 | 483,378 | |
| 10/3/2016 | Daniel Steines | CTO | Sell | 10,000 | $10.03 | $100,300.00 | 225,213 | |
| 10/3/2016 | Philipp Lang | CEO | Sell | 10,410 | $10.03 | $104,412.30 | 483,378 | |
| 9/16/2016 | Daniel Steines | Insider | Sell | 30,000 | $9.09 | $272,700.00 | 245,213 | |
| 8/17/2016 | Kenneth P Fallon III | Director | Sell | 4,000 | $8.44 | $33,760.00 | 92,222 | |
| 5/17/2016 | Robert Law III | SVP | Buy | 1,600 | $6.20 | $9,920.00 | 24,793 | |
(Data available from 1/1/2013 forward)
ConforMIS (NASDAQ CFMS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Brokerages Expect ConforMIS (CFMS) Will Post Quarterly Sales of $19.48 Million
www.americanbankingnews.com - May 16 at 2:53 AM |
| Zacks: Brokerages Anticipate ConforMIS (CFMS) Will Announce Earnings of -$0.21 Per Share
www.americanbankingnews.com - May 14 at 1:20 PM |
 | Form 4 ConforMIS Inc For: May 07 Filed by: Steines Daniel
www.streetinsider.com - May 10 at 8:06 AM |
| Analysts Set Expectations for ConforMIS's Q3 2018 Earnings (CFMS)
www.americanbankingnews.com - May 7 at 3:24 AM |
| BTIG Research Reiterates Buy Rating for ConforMIS (CFMS)
www.americanbankingnews.com - May 3 at 11:51 PM |
| ConforMIS (CFMS) Upgraded at ValuEngine
www.americanbankingnews.com - May 3 at 10:19 PM |
| Bradley Langdale Sells 9,465 Shares of ConforMIS (CFMS) Stock
www.americanbankingnews.com - May 3 at 8:45 PM |
| ConforMIS (CFMS) Issues Earnings Results
www.americanbankingnews.com - May 3 at 3:34 PM |
| ConforMIS (CFMS) PT Set at $4.00 by Oppenheimer
www.americanbankingnews.com - May 3 at 12:52 PM |
 | ConforMIS' (CFMS) CEO Mark Augusti on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 8:06 AM |
 | Edited Transcript of CFMS earnings conference call or presentation 2-May-18 8:30pm GMT
finance.yahoo.com - May 3 at 8:06 AM |
| ConforMIS: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 8:06 AM |
| Are ConforMIS Inc’s (NASDAQ:CFMS) Interest Costs Too High?
finance.yahoo.com - May 2 at 5:45 PM |
| Conformis Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 2 at 5:45 PM |
| ConforMIS (CFMS) to Release Earnings on Tuesday
www.americanbankingnews.com - May 1 at 2:08 AM |
| Insider Selling: ConforMIS (CFMS) Director Sells 651,212 Shares of Stock
www.americanbankingnews.com - April 30 at 10:10 PM |
| ConforMIS (CFMS) Insider Daniel Steines Sells 277,064 Shares
www.americanbankingnews.com - April 30 at 10:10 PM |
| ConforMIS (CFMS) Director Sells $115,161.28 in Stock
www.americanbankingnews.com - April 30 at 10:10 PM |
| Insider Selling: ConforMIS (CFMS) CTO Sells 13,900 Shares of Stock
www.americanbankingnews.com - April 30 at 10:10 PM |
| ConforMIS (CFMS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 29 at 8:24 AM |
| Brokerages Expect ConforMIS (CFMS) Will Announce Quarterly Sales of $19.51 Million
www.americanbankingnews.com - April 29 at 5:50 AM |
| -$0.26 Earnings Per Share Expected for ConforMIS (CFMS) This Quarter
www.americanbankingnews.com - April 27 at 1:29 AM |
| ConforMIS's (CFMS) "Hold" Rating Reiterated at BTIG Research
www.americanbankingnews.com - April 20 at 2:25 PM |
| ConforMIS (CFMS) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 9:10 PM |
| Conformis to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 2, 2018
finance.yahoo.com - April 12 at 5:51 PM |
| $19.51 Million in Sales Expected for ConforMIS (CFMS) This Quarter
www.americanbankingnews.com - April 12 at 5:19 AM |
 | Benzinga's Top Upgrades, Downgrades For April 10, 2018
www.benzinga.com - April 10 at 5:46 PM |
| UPDATE: Canaccord Genuity Upgrades ConforMIS (CFMS) to Buy
www.streetinsider.com - April 10 at 5:46 PM |
| ConforMIS (CFMS) Rating Increased to Buy at Canaccord Genuity
www.americanbankingnews.com - April 10 at 8:29 AM |
| -$0.26 EPS Expected for ConforMIS (CFMS) This Quarter
www.americanbankingnews.com - April 10 at 3:13 AM |
| ConforMIS Inc (CFMS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 9:58 AM |
| ConforMIS (CFMS) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 3 at 8:45 PM |
| ConforMIS (CFMS) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 3 at 5:52 PM |
| ConforMIS (CFMS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 2 at 8:40 PM |
| ConforMIS (CFMS) Given Hold Rating at BTIG Research
www.americanbankingnews.com - April 2 at 8:39 AM |
| JPMorgan Chase Downgrades ConforMIS (CFMS) to Underweight
www.americanbankingnews.com - March 31 at 11:54 AM |
| Market Trends Toward New Normal in ConforMIS, Equity Commonwealth, SendGrid, Granite Point Mortgage Trust, Stewart Information Services, and South State — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - March 30 at 8:03 AM |
| ConforMIS Inc (CFMS) Expected to Post Quarterly Sales of $19.51 Million
www.americanbankingnews.com - March 26 at 7:53 AM |
| ConforMIS (CFMS) Earns "Buy" Rating from Oppenheimer
www.americanbankingnews.com - March 22 at 4:09 PM |
| ConforMIS (CFMS) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:16 PM |
| ConforMIS's (CFMS) "Hold" Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - March 12 at 9:22 PM |
 | Quotidian Technical Highlights on Selected Medical Supplies Stocks -- Baxter, ConforMIS, DENTSPLY SIRONA, and ... - PR Newswire (press release)
www.prnewswire.com - March 12 at 6:58 AM |
| ConforMIS Inc (CFMS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 10 at 7:36 AM |
 | Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the ... - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:20 AM |
| Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the Conformis iTotal CR
finance.yahoo.com - March 7 at 8:20 AM |
| Conformis iTotal CR Knee Replacement System Awarded “3A” Rating from the Orthopaedic Data Evaluation Panel in ... - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:24 AM |
| Conformis iTotal CR Knee Replacement System Awarded “3A” Rating from the Orthopaedic Data Evaluation Panel in the United Kingdom
finance.yahoo.com - March 1 at 8:24 AM |
| ConforMIS (CFMS) Coverage Initiated by Analysts at Cowen
www.americanbankingnews.com - February 21 at 10:59 AM |
| ConforMIS Inc (CFMS) Expected to Announce Quarterly Sales of $19.51 Million
www.americanbankingnews.com - February 20 at 11:44 AM |
| Zacks: Brokerages Anticipate ConforMIS Inc (CFMS) to Announce -$0.25 Earnings Per Share
www.americanbankingnews.com - February 18 at 5:08 AM |
ConforMIS (NASDAQ:CFMS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ConforMIS (NASDAQ:CFMS) Income Statement, Balance Sheet and Cash Flow Statement
ConforMIS (NASDAQ CFMS) Stock Chart for Monday, May, 21, 2018
Loading chart…
